{"nctId":"NCT01715805","briefTitle":"Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)","startDateStruct":{"date":"2012-11-15","type":"ACTUAL"},"conditions":["Major Depressive Disorder"],"count":1022,"armGroups":[{"label":"Placebo + ADT Lead-in","type":"OTHER","interventionNames":["Drug: Placebo","Drug: Antidepressant Therapy (ADT)"]},{"label":"Placebo + ADT (Double-Blind)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Antidepressant Therapy (ADT)"]},{"label":"Cariprazine + ADT (Double-Blind)","type":"EXPERIMENTAL","interventionNames":["Drug: Cariprazine","Drug: Antidepressant Therapy (ADT)"]},{"label":"Placebo + ADT (Continued Treatment)","type":"OTHER","interventionNames":["Drug: Placebo","Drug: Antidepressant Therapy (ADT)"]}],"interventions":[{"name":"Cariprazine","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Antidepressant Therapy (ADT)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who have provided consent prior to any specific procedure\n* Meet the The Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR) criteria for Major Depressive Disorder (MDD)\n* Have a minimum score of 20 on 17-Item Hamilton Depression (HAMD-17) rating scale at Visits 1 and 2\n\nExclusion Criteria:\n\n* Patients who do not meet DSM-IV-TR criteria for MDD","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Montgomery-Asberg Depression Rating Scale (MADRS) at Baseline in the Double-Blind Period","description":"The MADRS is a clinician-rated scale to assess depressive symptomatology during the past week. Patients are rated on 10 items to assess feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating and lack of interest. Each item is scored on a 7-point scale. A score of 0 indicates the absence of symptoms, and a score of 6 indicates symptoms of maximum severity for a total possible score of 0 to 60.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.2","spread":"6.1"},{"groupId":"OG001","value":"25.4","spread":"5.5"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) in the Double-Blind Period","description":"The MADRS is a clinician-rated scale to assess depressive symptomatology during the past week. Participants are rated on 10 items to assess feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating and lack of interest. Each item is scored on a 7-point scale. A score of 0 indicates the absence of symptoms, and a score of 6 indicates symptoms of maximum severity for a total possible score of 0 to 60. A negative change from Baseline indicates improvement. Mixed-effects model for repeated measures (MMRM) with treatment group, study center, visit, and treatment group-by-visit interaction as fixed effects, and the baseline value and baseline by-visit interaction as the covariates was used for analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.5","spread":"0.5"},{"groupId":"OG001","value":"-7.7","spread":"0.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Sheehan Disability Scale (SDS) Score in the Double-Blind Period","description":"The Sheehan Disability Scale (SDS) is a 3-item patient-rated questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum from 0 (no impairment) to 10 (most severe). The 3 individual scores are summed for a total possible score of 0 (unimpaired) to 30 (highly impaired). A negative change from Baseline indicates improvement. MMRM with treatment group, study center, visit, and treatment group-by-visit interaction as fixed effects, and the baseline value and baseline by-visit interaction as the covariates was used for analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"0.5"},{"groupId":"OG001","value":"-3.7","spread":"0.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":1022},"commonTop":["Headache","Nausea","Insomnia","Diarrhoea","Akathisia"]}}}